Visual analytics of flight trajectories for uncovering decision making strategies

In air traffic management and control, movement data describing actual and planned flights are used for planning, monitoring and post-operation analysis purposes with the goal of increased efficient utilization of air space capacities (in terms of delay reduction or flight efficiency), without compromising the safety of passengers and cargo, nor timeliness of flights. From flight data, it is possible to extract valuable information concerning preferences and decision making of airlines (e.g. route choice) and air traffic managers and controllers (e.g. flight rerouting or optimizing flight times), features whose understanding is intended as a key driver for bringing operational performance benefits. In this paper, we propose a suite of visual analytics techniques for supporting assessment of flight data quality and data analysis workflows centred on revealing decision making preferences

Impact of activation cross-section uncertainties on the tritium production in the HFTM specimen cells

The prediction of the tritium production is required for handling procedures of samples, safety & maintenance and licensing of the International Fusion Materials Irradiation Facility (IFMIF). A comparison of the evaluated tritium production cross-sections with available experimental data from the EXFOR data base has shown insufficient validation. And significant discrepancies in evaluated cross-section libraries, including lack of tritium production reactions for some important elements, were found. Here, we have addressed an uncertainty analysis to draw conclusions on the reliability of the tritium prediction under the potential impact of activation cross-section uncertainties. We conclude that there is not sufficient experimental validation of the evaluated tritium production cross-sections, especially for iron and sodium. Therefore a dedicated experimental validation program for those elements should be desirable

Ten years since the introduction of therapeutic hypothermia in neonates with perinatal hypoxic-ischaemic encephalopathy in Spain

More than a decade has passed since therapeutic hypothermia (TH) was introduced in Spain; this is the only neuroprotective intervention that has become standard practice in the treatment of perinatal hypoxic-ischaemic encephalopathy (HIE). This article aims to provide a current picture of the technique and to address the controversies surrounding its use. In the last 10 years, TH has been successfully implemented in the vast majority of tertiary hospitals in Spain, and more than 85% of newborns with moderate or severe HIE currently receive the treatment. The factors that can improve the efficacy of TH include early treatment onset (first 6 hours of life) and the control of comorbid factors associated with perinatal asphyxia. In patients with moderate HIE, treatment onset after 6 hours seems to have some neuroprotective efficacy. TH duration longer than 72 hours or deeper hypothermia do not offer greater neuroprotective efficacy, but instead increase the risk of adverse effects. Unclarified aspects are the sedation of patients during TH, the application of the treatment in infants with mild HIE, and its application in other scenarios. Prognostic information and time frame are one of the most challenging aspects. TH is universal in countries with sufficient economic resources, although certain unresolved controversies remain. While the treatment is widespread in Spain, there is a need for cooling devices for the transfer of these patients and their centralisationSe cumple ahora más de una década del inicio de la hipotermia terapéutica (HT) en España, la única intervención neuroprotectora que ha venido a ser práctica estándar en el tratamiento de la encefalopatía hipóxico-isquémica perinatal (EHI). El objetivo de este artículo es ofrecer un panorama actual y presentar las controversias surgidas alrededor de la aplicación de esta terapia. En esta década se ha implantado con éxito la HT en la gran mayoría de los hospitales terciarios de España y más del 85% de los recién nacidos con EHI moderada-grave reciben esta terapia. Entre los aspectos que pueden mejorar la eficacia de la HT están su inicio precoz dentro de las primeras 6 horas de vida y el control de factores comórbidos asociados a la asfixia perinatal. En los pacientes con EHI moderada el inicio después de las 6 horas parece mantener cierta eficacia neuroprotectora. Una duración de la HT mayor de 72 horas o un enfriamiento más profundo no ofrecen mayor eficacia neuroprotectora y aumentan el riesgo de efectos adversos. Persiste la controversia acerca de la sedación durante la HT, la aplicación de esta intervención a los neonatos con EHI leve y en otros escenarios. La información pronóstica y su marco temporal es uno de los aspectos más desafiantes. La HT es universal en países con recursos económicos, aunque existen puntos de controversia no resueltos. Si bien es un tratamiento generalizado en nuestro país, falta disponer de dispositivos para el traslado de estos pacientes y su centralizació

Transport demand evolution in Europe – factors of change, scenarios and challenges

In the transport sector, where change comes with inertia and investments are made with a long term perspective, decision makers need to consider how the future may look like in the very long term. The work presented in this paper is a scenario analysis focusing on the evolution of transport demand towards 2050, aiming to identify related challenges for European industrial and policy players. It follows up on the work of other recent attempts to study the future of transport from a European perspective, integrating findings from these studies, updating new trends and applying a specific scenario analysis methodology relying also on expert consultation. The diversity of the scenarios created unfolds aspects of the future transport system with rather different outcomes on issues like the volume of transport, travel motives, the prevalent spatial scales of transport and logistics, people’s preferences towards different transport attributes, the relevancy of the State versus the private initiative in transport production, the level of competition, or the relative importance of environment and resource scarcity in setting an agenda for innovation and regulations. Beyond the subsequent challenges and opportunities identified in this work, the scenarios developed may be a useful basis for individual actors of distinct backgrounds to build their own specific futures, supporting them in defining strategies for the future.JRC.J.1-Economics of Climate Change, Energy and Transpor

Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis

Cancer-associated fibroblasts (CAF) remain a poorly characterized, heterogeneous cell population. Here we characterized two previously described tumor-promoting CAF sub-types, smooth muscle actin (SMA)-positive myofibroblasts and senescent fibroblasts, identifying a novel link between the two

Recommendations for MYRRHA relevant cross section data to the JEFF project

Within the framework of Work Package 10 of the EC FP7 CHANDA project, nuclear data of importance for the operation of MYRRHA, a lead-bismuth cooled accelerator driven reactor under development at SCK•CEN (BE), were studied. Based on data in the main nuclear data libraries, i.e. JEFF, JENDL, ENDF/B and BROND, and in the TENDL and CIELO libraries and on experimental data reported in the literature, recommendations to the JEFF project were made for several nuclides of interest to the MYRRHA reactor.JRC.G.2-Standards for Nuclear Safety, Security and Safeguard

First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

Aim: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2–12). Methods: 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2–12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2–12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2–12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Results: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2–12 dose categories (p7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of =6, the model did not change. Conclusion: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium

Background:Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. Methods:Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. Results:Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95 confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. Conclusion:Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2. © 2014 Cancer Research UK